H.C. Wainwright & Co., LLC

We are pleased to have served as Co-Manager for Disc Medicine’s $225.5 Million Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions

Dr. Manish Sagar, Professor of Medicine, Virology, Immunology, and Microbiology at Boston University School of Medicine, will be featured in our Biotech Breakthroughs series this Friday, January 31 at 10am EST. Moderated by HCW Research Analyst Patrick Trucchio, the discussion will explore various treatment approaches for the novel human immunodeficiency virus (HIV), with Dr. Sagar sharing his expertise in HIV-1 transmission and the associated biological mechanisms. Biotech Breakthroughs is a monthly discovery series featuring key opinion leaders, focusing on novel technologies, modalities, and delivery mechanisms, typically aligned with key value-generating data readouts that have the potential to enable new treatments across multiple disease areas. Register for the series and stay updated here: https://lnkd.in/e7x8Pev6

For 11 consecutive years, H.C. Wainwright & Co. has maintained our position as #1 Investment Bank for confidentially marketed public offerings, registered directs, private placements, and ATM offerings in PlacementTracker’s Market League Tables. Since the start of 2024, we executed over 345 transactions totaling over $15 billion in transaction value. The HCW team has been ranked #1 underwriter/ placement agent by deal volume cumulatively since 1998. We are honored to maintain this top position and continue to serve public and private companies across multiple sectors and regions, providing corporate finance, strategic advisory and related services. View all of our transactions online at www.hcwco.com/transactions. Source: PlacementTracker

Join us on Tuesday, January 28 at 11am EST for an HCW@Home virtual fireside chat, featuring a panel of experts from Gyre Therapeutics. Chief Executive Officer Han Ying, Regulatory Affairs Consultant Suzana Corritori, and Clinical Development Consultant Que (Roger) Liu will be joined by HCW Research Analyst Ed Arce for an in-depth discussion on Gyre’s lead drug, F351. They will cover the latest advancements, the drug's key indications, and the company’s strategic outlook. Please visit https://lnkd.in/e2QiCud8 to register.

Next Tuesday, BTCS Inc. (Nasdaq: BTCS) will be participating in our HCW@Home Series. The virtual fireside chat will be hosted by covering Research Analyst Kevin Dede and feature BTCS Chief Executive Officer Charles Allen; Vice President of Engineering Ben Hunter; and former Ethereum Ecosystem Lead and current Blockdaemon consultant Freddy Zwanzger. The discussion will highlight the recent innovations to blockchain technology, insights into the rapidly evolving Ethereum ecosystem, and BTCS’ role as a participant in Ethereum’s infrastructure.   To join, please register at https://lnkd.in/gmnTXHW6

We are excited to welcome Victoria Meissner, MD to the H.C. Wainwright & Co. team as Vice President in our Healthcare Investment Banking group! Victoria joins us with an impressive breadth of expertise across Healthcare Investment Banking, Biotech Strategy, Investor Relations, Capital Markets Advisory and Medical Sciences. Most recently, she served as Vice President of Strategy and Head of Investor Relations at BioNTech SE, where she led a global team. A native of Germany/Austria, Victoria took her academic journey to Chicago after earning her M.D. from the Medical University of Vienna. Her Ph.D. research at the University of Illinois Hospital at Chicago, div. of Transplant Surgery, focused on diabetes and pancreatic islet transplantation. Victoria also co-led fundraising efforts for Chicago Diabetes Project, aimed at helping patients in need of a functional cure and worked towards regulatory approval of now FDA-approved cellular therapy Lantidra. Following her academic career, Victoria transitioned to the world of investor relations and capital markets advisory for biotech and pharma companies, and further honed her skills in healthcare investment banking at leading institutions such as Jefferies and Oppenheimer. We are thrilled to have Victoria bring her depth of scientific experience, strategic insights, and leadership to HCW. Please join us in welcoming her to the team!

We are pleased to have served as Lead Manager for uniQure’s $75 Million Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions

Institutional investors are invited to join us next Tuesday, January 14th, for an exclusive series of fireside chats with the leadership teams of Absci, Korro Bio, Inc., and Neumora. These insightful sessions, led by our covering research analysts, will provide a deep dive into each company's latest innovations and strategic vision.   Food will be provided, with limited seats available. For more information and to RSVP, please email corporateaccess@hcwco.com.   #JPM2025 #JPM25 #JPMHealthcare

We are pleased to have served as the Exclusive Placement Agent for BioLineRx’s $10 Million Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions

We are pleased to have served as the Exclusive Placement Agent for Bionano Genomics’ $10 Million Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions